Pakistan Stock Exchange Ltd · PSX:PSX
Pakistan Stock Exchange — GSK Consumer Healthcare Pakistan — 9M 2022 Earnings Presentation
15 slides from Pakistan Stock Exchange's earnings presentation, November 2022
Slide 1: GSK Consumer Healthcare Pakistan Limited
GSK Consumer Healthcare Pakistan Limited Nine months ended September 30, 2022 Corporate Briefing Session
Slide 2: Agenda
Agenda Our Story Business Overview Key Financials Question and Answers 2
Slide 3: Our Story
Our Story Vision, Values and Strategy
Slide 4: Our Story and Key facts
Our Story and Key facts GSK Consumer business demerged from GSK Pakistan Limited in 2015 and formed two entities; • GSK Consumer Healthcare Pakistan Limited (GSK CHC) and • GSK OTC Private Limited (GSK OTC) Transfer of Marketing GSK CHC starts operations as Authorization and Jamshoro an independent
Slide 5: Corporate Information
Corporate Information Human Resource Integration Supply & Audit Committee Remuneration and Network Optimization Management Committee Nomination Committee Committee • Ms. Ayesha Aziz (Chair) • Syed Anwar Mahmood • Oussama Abbas (Chair) • Farhan M. Haroon (CEO) • M.Z. Moin Mohajir (Chair) • Farhan Muh
Slide 6: Our Local Footprint
Our Local Footprint Registered Office: Sandoz Nagar, Petaro Road, Jamshoro, Sindh – 76100. Sales Offices: Karachi, Lahore and Islamabad. Factory: State of the art facility for manufacturing and packaging. Serving to Pakistan, Vietnam and Philippines markets. 6
Slide 7: Business Overview
Business Overview
Slide 8: Brands Portfolio
Brands Portfolio FMCG OVER THE COUNTER (Regulated by DRAP) (Represents 14% business) (Represents 86%* business) Nutrition & Skin Health Respiratory Pain Relief Oral Care Digestive 8 * Includes toll business representing 12% of the total business.
Slide 9: Portfolio wise Sales – September 2021 Vs September 2022
Portfolio wise Sales – September 2021 Vs September 2022 Maintaining the upward trend by doing what matter most! PKR in million Total Company Net Sales Net Sales OTC +16% vs last year Portfolio Net Sales FMCG +19% vs last year Portfolio Net Sales Toll +19% vs last year (Novartis) + Exports -6% vs las
Slide 10: Key Brands Performance
Key Brands Performance Top 3 Brands contribute 82% to Total turnover in Pain Relief Category Prescribed Calcium supplement in Sensitivity Category >10% Sales Growth >20% Sales Growth >15% Sales Growth *IQVIA MAT Aug ’22
Slide 11: Key Financials
Key Financials Presentation title 11
Slide 12: Key Financial Highlights
Key Financial Highlights PKR 21bn PKR 3.5bn PKR 2.9bn Total Turnover (17% of sales) OPEX +16% vs. LY Gross Margin +9% vs. LY -11% vs. LY PKR 0.4bn PKR (0.58)* PBT Loss per share -11% of sales vs. -PKR 14.6 vs. LY LY * This includes super tax impact including deferred tax amounting to Rs. 283 million
Slide 13: GP Reconciliation – YTD September 2022
GP Reconciliation – YTD September 2022 2021 2022 GLYCERINE 227% 27.7% 16.9% CITRIC ACID 214% PVC 65% G.P% impact PEG 27% Higher Cost of Procurement 8.1% Other Cost Escalations 2.7% 13
Slide 14: Outlook and Challenges
Outlook and Challenges Global commodity prices including logistics remain challenging Continued currency devaluation Absence of swift approval of hardship cases in urgent situations High inflationary environment Unpredictable tax regime 15
Slide 15: THANK YOU! Q&A
THANK YOU! Q&A
GSK Consumer Healthcare Pakistan — 9M 2022 Earnings Presentation on 6ix